NICE says nay to Sprycel, yea to discounted Tasigna

The U.K.'s cost-effectiveness watchdog rejected Bristol-Myers Squibb's ($BMY) Sprycel for chronic myeloid leukemia, but accepted Novartis' ($NVS) Glivec and its follow-up drug Tasigna after the Swiss drugmaker offered a discount on the latter. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.